Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer – – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions – TOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc....
Short extract only — this publisher licenses its text. Read the full release at the source.
Cancel anytime · CA$99/month


